A bispecific antibody has entered the HER2 fray with a differentiated profile from traditional agents and a chance to challenge AstraZeneca and Daiichi Sankyo’s star antibody-drug conjugate Enhertu.

Johnson & Johnson has agreed a $850 million deal to acquire Proteologix that will give it a pair of early-stage bispecific antibodies with immunology applications, including a drug heading for ...

Johnson & Johnson's much-touted crop of bispecific antibodies for cancer generated its first commercial product in May, and the drugmaker has now filed for FDA approval of a second candidate.

The British Library and Yuewen have launched a landmark three-year collaboration, Literature in the Digital Age, to enhance cultural exchange between the UK and China and promote the co-creation of ...

1Department of Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa, Japan.

Jazz Phar­ma­ceu­ti­cals earned an FDA ap­proval on Wednes­day for zanidatam­ab, the HER2-tar­get­ed bis­pe­cif­ic an­ti­body it picked up from Zymeworks for $50 mil­lion … ...